<p>Neo Ivy Capital Management 在最近向证券交易委员会提交的 13F 表格中披露，在第四季度将其在 Hims &amp; Hers Health, Inc.（纽约证券交易所代码：HIMS - 免费报告）的持股增加了 145.4%。该机构投资者在此期间额外购买了 98,798 股后，持有该公司 166,734 股股票。Hims &amp; Hers Health 约占 Neo Ivy Capital Management 投资组合的 0.8%，使其成为该投资组合中第 21 大持仓。截止最近一个季度末，Neo Ivy Capital Management 持有的 Hims &amp; Hers Health 的股份约占 0.08%，价值 4,031,000 美元。</p>
<p>获取 <strong>Hims &amp; Hers Health</strong> 的提醒：</p>
<ul>
<li>在 UnitedHealth 抛售后，Hims &amp; Hers 的股票会好吗？</li>
</ul>
<p>其他几家大型投资者也对 HIMS 的持仓进行了调整。Crewe Advisors LLC 在第四季度购买了 Hims &amp; Hers Health 的新股份，价值约 28,000 美元。Raleigh Capital Management Inc.在第四季度将其在 Hims &amp; Hers Health 的持仓提高了 1,100.0%。Raleigh Capital Management Inc.现在持有 1,200 股该公司的股票，价值 29,000 美元，此前在上个季度又购买了 1,100 股。Blume Capital Management Inc.在第四季度将其在 Hims &amp; Hers Health 的持仓提高了 100.0%。Blume Capital Management Inc.现在持有 1,200 股该公司的股票，价值 29,000 美元，此前在上个季度又购买了 600 股。Smartleaf Asset Management LLC 在第四季度将其在 Hims &amp; Hers Health 的持仓提高了 4,415.6%。Smartleaf Asset Management LLC 现在持有 1,445 股该公司的股票，价值 36,000 美元，此前在上个季度又购买了 1,413 股。最后，Summit Securities Group LLC 在第四季度购买了 Hims &amp; Hers Health 的新股份，价值约 38,000 美元。目前，63.52% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>内部人士下注</h2>
<p>在 Hims &amp; Hers Health 的其他新闻中，首席执行官 Andrew Dudum 在 5 月 16 日星期五出售了 47,534 股该公司的股票。股票以 58.25 美元的平均价格出售，总交易额为 2,768,855.50 美元。出售完成后，首席执行官现在持有 285,194 股该公司的股票，价值 16,612,550.50 美元。这代表其持股减少了 14.29%。该交易在向证券交易委员会的备案中披露，相关信息可在 SEC 网站上找到。此外，内部人士 Patrick Harrison Carroll 在 3 月 18 日星期二出售了 23,287 股该股票。股票以 34.31 美元的平均价格出售，总价值为 798,976.97 美元。出售后，内部人士现在持有 209,661 股该公司的股票，价值约 7,193,468.91 美元。这代表其持仓减少了 10.00%。该出售的披露信息可以在这里找到。在过去 90 天内，内部人士共出售了 618,936 股公司股票，价值 25,182,692 美元。公司内部人士持有公司股票的 13.71%。</p>
<h2>Hims &amp; Hers Health 股票下跌 7.6%</h2>
<ul>
<li>Hims &amp; Hers 股票图表显示强劲的看涨延续</li>
</ul>
<p>Hims &amp; Hers Health, Inc.（纽约证券交易所代码：HIMS）周五开盘价为 53.58 美元。Hims &amp; Hers Health 的 52 周低点为 13.47 美元，52 周高点为 72.98 美元。该股票的市值为 119.9 亿美元，市盈率为 121.78，贝塔值为 1.84。该公司的 50 日移动平均线为 37.48 美元，200 日移动平均线为 34.77 美元。</p>
<p>Hims &amp; Hers Health（纽约证券交易所代码：HIMS - 获取免费报告）最后一次公布季度财报是在 5 月 5 日星期一。该公司报告每股收益（EPS）为 0.20 美元，超出市场共识预期的 0.12 美元，超出幅度为 0.08 美元。该公司季度收入为 5.8601 亿美元，而分析师预期为 5.3521 亿美元。Hims &amp; Hers Health 的股本回报率为 10.97%，净利润率为 8.19%。与去年同期相比，Hims &amp; Hers Health 的收入增长了 110.7%。在去年同期，该公司每股收益为 0.05 美元。平均而言，卖方分析师预计 Hims &amp; Hers Health, Inc.在当前财政年度将发布 0.29 美元的每股收益。</p>
<h2>分析师评级上调与下调</h2>
<ul>
<li>Hims &amp; Hers 股票因基本面和挤压潜力而上涨</li>
</ul>
<p>多家研究机构最近对 HIMS 进行了评论。华尔街 Zen 在周四的研究报告中将 Hims &amp; Hers Health 的评级从 “持有” 上调至 “买入”。Leerink Partners 在 2 月 25 日的研究报告中将 Hims &amp; Hers Health 的目标价格从 24.00 美元上调至 40.00 美元，并给予该股票 “市场表现” 的评级。美国银行在 4 月 29 日的研究报告中将 Hims &amp; Hers Health 的目标价格从 22.00 美元上调至 26.00 美元，并给予该股票 “表现不佳” 的评级。TD Cowen 在 4 月 29 日的研究报告中将 Hims &amp; Hers Health 的评级从 “买入” 下调至 “持有”，并将该股票的目标价格从 44.00 美元下调至 30.00 美元。最后，Needham &amp; Company LLC 在 5 月 6 日的研究报告中重申了 “买入” 评级，并将 Hims &amp; Hers Health 的目标价格设定为 61.00 美元。两家股票研究分析师对该股票给予了卖出评级，八家给予了持有评级，四家给予了买入评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “持有”，平均目标价格为 37.67 美元。</p>
<p><strong>获取我们关于 Hims &amp; Hers Health 的最新研究报告</strong></p>
<h2>关于 Hims &amp; Hers Health</h2>
<p>（免费报告）</p>
<p>Hims &amp; Hers Health, Inc.运营一个远程医疗咨询平台。它将消费者与医疗专业人员连接，使他们能够获得心理健康、性健康、皮肤病学和初级护理的医疗服务。该公司成立于 2017 年，总部位于加利福尼亚州旧金山。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票，而不是 Hims &amp; Hers Health</li>
<li>投资于 5G 技术的顶级股票</li>
<li>NVIDIA 的 AI 机器人跃进：两只股票将乘风而起</li>
<li>最具波动性的股票，投资者需要知道什么</li>
<li>Joby 股票的动荡：近期下跌背后的原因是什么？</li>
<li>十月值得考虑购买的三只股票</li>
<li>为什么嘉年华可能是终极非科技增长股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhJTVM?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhJTVM"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 $1,000 在 Hims &amp; Hers Health 吗？</h2>
<p>在考虑 Hims &amp; Hers Health 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Hims &amp; Hers Health 并不在名单上。</p>
<p>虽然 Hims &amp; Hers Health 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

HIMS

<p>Neo Ivy Capital Management 在第四季度将其在 Hims & Hers Health, Inc. (NYSE:HIMS) 的持股增加了 145.4%，在收购了 98,798 股后，持有 166,734 股。这项投资占其投资组合的 0.8%。其他投资者也调整了在 HIMS 的持仓。首席执行官 Andrew Dudum 出售了 47,534 股，减少了 14.29% 的持股。Hims & Hers 的股票目前下跌 7.6%，市值为 119.9 亿美元，市盈率为 121.78。该公司报告了强劲的收益，超出预期，上一季度每股收益为 0.20 美元，收入为 5.8601 亿美元</p>

<p>Neo Ivy Capital Management grew its holdings in Hims &amp; Hers Health, Inc. (NYSE:HIMS - Free Report) by 145.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities &amp; Exchange Commission. The institutional investor owned 166,734 shares of the company's stock after acquiring an additional 98,798 shares during the period. Hims &amp; Hers Health comprises about 0.8% of Neo Ivy Capital Management's investment portfolio, making the stock its 21st biggest position. Neo Ivy Capital Management owned about 0.08% of Hims &amp; Hers Health worth $4,031,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>Neo Ivy Capital Management 在最近向证券交易委员会提交的 13F 表格中披露，在第四季度将其在 Hims &amp; Hers Health, Inc.（纽约证券交易所代码：HIMS - 免费报告）的持股增加了 145.4%。该机构投资者在此期间额外购买了 98,798 股后，持有该公司 166,734 股股票。Hims &amp; Hers Health 约占 Neo Ivy Capital Management 投资组合的 0.8%，使其成为该投资组合中第 21 大持仓。截止最近一个季度末，Neo Ivy Capital Management 持有的 Hims &amp; Hers Health 的股份约占 0.08%，价值 4,031,000 美元。</p>
</div><p>Get <strong>Hims &amp; Hers Health</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Hims &amp; Hers Health</strong> 的提醒：</p>
</div><ul>
<li>Will Hims &amp; Hers Stock Be Okay After UnitedHealth's Sell-Off?</li>
</ul>
<div class="lb-trans"><ul>
<li>在 UnitedHealth 抛售后，Hims &amp; Hers 的股票会好吗？</li>
</ul>
</div><p>Several other large investors have also made changes to their positions in HIMS. Crewe Advisors LLC purchased a new stake in shares of Hims &amp; Hers Health in the fourth quarter worth about $28,000. Raleigh Capital Management Inc. lifted its position in shares of Hims &amp; Hers Health by 1,100.0% in the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company's stock worth $29,000 after buying an additional 1,100 shares in the last quarter. Blume Capital Management Inc. lifted its position in shares of Hims &amp; Hers Health by 100.0% in the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock worth $29,000 after buying an additional 600 shares in the last quarter. Smartleaf Asset Management LLC lifted its position in shares of Hims &amp; Hers Health by 4,415.6% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company's stock worth $36,000 after buying an additional 1,413 shares in the last quarter. Finally, Summit Securities Group LLC purchased a new stake in shares of Hims &amp; Hers Health in the fourth quarter worth about $38,000. 63.52% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他几家大型投资者也对 HIMS 的持仓进行了调整。Crewe Advisors LLC 在第四季度购买了 Hims &amp; Hers Health 的新股份，价值约 28,000 美元。Raleigh Capital Management Inc.在第四季度将其在 Hims &amp; Hers Health 的持仓提高了 1,100.0%。Raleigh Capital Management Inc.现在持有 1,200 股该公司的股票，价值 29,000 美元，此前在上个季度又购买了 1,100 股。Blume Capital Management Inc.在第四季度将其在 Hims &amp; Hers Health 的持仓提高了 100.0%。Blume Capital Management Inc.现在持有 1,200 股该公司的股票，价值 29,000 美元，此前在上个季度又购买了 600 股。Smartleaf Asset Management LLC 在第四季度将其在 Hims &amp; Hers Health 的持仓提高了 4,415.6%。Smartleaf Asset Management LLC 现在持有 1,445 股该公司的股票，价值 36,000 美元，此前在上个季度又购买了 1,413 股。最后，Summit Securities Group LLC 在第四季度购买了 Hims &amp; Hers Health 的新股份，价值约 38,000 美元。目前，63.52% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><p>In other Hims &amp; Hers Health news, CEO Andrew Dudum sold 47,534 shares of the company's stock in a transaction on Friday, May 16th. The stock was sold at an average price of $58.25, for a total transaction of $2,768,855.50. Following the completion of the sale, the chief executive officer now owns 285,194 shares in the company, valued at $16,612,550.50. This represents a 14.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is available at the SEC website. Also, insider Patrick Harrison Carroll sold 23,287 shares of the stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $34.31, for a total value of $798,976.97. Following the sale, the insider now owns 209,661 shares of the company's stock, valued at approximately $7,193,468.91. This represents a 10.00% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 618,936 shares of company stock worth $25,182,692 over the last 90 days. Company insiders own 13.71% of the company's stock.</p>
<div class="lb-trans"><p>在 Hims &amp; Hers Health 的其他新闻中，首席执行官 Andrew Dudum 在 5 月 16 日星期五出售了 47,534 股该公司的股票。股票以 58.25 美元的平均价格出售，总交易额为 2,768,855.50 美元。出售完成后，首席执行官现在持有 285,194 股该公司的股票，价值 16,612,550.50 美元。这代表其持股减少了 14.29%。该交易在向证券交易委员会的备案中披露，相关信息可在 SEC 网站上找到。此外，内部人士 Patrick Harrison Carroll 在 3 月 18 日星期二出售了 23,287 股该股票。股票以 34.31 美元的平均价格出售，总价值为 798,976.97 美元。出售后，内部人士现在持有 209,661 股该公司的股票，价值约 7,193,468.91 美元。这代表其持仓减少了 10.00%。该出售的披露信息可以在这里找到。在过去 90 天内，内部人士共出售了 618,936 股公司股票，价值 25,182,692 美元。公司内部人士持有公司股票的 13.71%。</p>
</div><h2>Hims &amp; Hers Health Stock Down 7.6%</h2>
<div class="lb-trans"><h2>Hims &amp; Hers Health 股票下跌 7.6%</h2>
</div><ul>
<li>Hims &amp; Hers Stock Chart Points to Strong Bullish Continuation</li>
</ul>
<div class="lb-trans"><ul>
<li>Hims &amp; Hers 股票图表显示强劲的看涨延续</li>
</ul>
</div><p>Shares of NYSE:HIMS opened at $53.58 on Friday. Hims &amp; Hers Health, Inc. has a 52-week low of $13.47 and a 52-week high of $72.98. The stock has a market cap of $11.99 billion, a P/E ratio of 121.78 and a beta of 1.84. The business's 50 day moving average is $37.48 and its 200 day moving average is $34.77.</p>
<div class="lb-trans"><p>Hims &amp; Hers Health, Inc.（纽约证券交易所代码：HIMS）周五开盘价为 53.58 美元。Hims &amp; Hers Health 的 52 周低点为 13.47 美元，52 周高点为 72.98 美元。该股票的市值为 119.9 亿美元，市盈率为 121.78，贝塔值为 1.84。该公司的 50 日移动平均线为 37.48 美元，200 日移动平均线为 34.77 美元。</p>
</div><p>Hims &amp; Hers Health (NYSE:HIMS - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The company reported $0.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.12 by $0.08. The company had revenue of $586.01 million for the quarter, compared to analysts' expectations of $535.21 million. Hims &amp; Hers Health had a return on equity of 10.97% and a net margin of 8.19%. Hims &amp; Hers Health's revenue was up 110.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.05 earnings per share. On average, sell-side analysts anticipate that Hims &amp; Hers Health, Inc. will post 0.29 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Hims &amp; Hers Health（纽约证券交易所代码：HIMS - 获取免费报告）最后一次公布季度财报是在 5 月 5 日星期一。该公司报告每股收益（EPS）为 0.20 美元，超出市场共识预期的 0.12 美元，超出幅度为 0.08 美元。该公司季度收入为 5.8601 亿美元，而分析师预期为 5.3521 亿美元。Hims &amp; Hers Health 的股本回报率为 10.97%，净利润率为 8.19%。与去年同期相比，Hims &amp; Hers Health 的收入增长了 110.7%。在去年同期，该公司每股收益为 0.05 美元。平均而言，卖方分析师预计 Hims &amp; Hers Health, Inc.在当前财政年度将发布 0.29 美元的每股收益。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级上调与下调</h2>
</div><ul>
<li>Hims &amp; Hers Stock Rises on Fundamentals and Squeeze Potential</li>
</ul>
<div class="lb-trans"><ul>
<li>Hims &amp; Hers 股票因基本面和挤压潜力而上涨</li>
</ul>
</div><p>A number of research firms recently commented on HIMS. Wall Street Zen upgraded Hims &amp; Hers Health from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research report on Thursday. Leerink Partners boosted their price objective on Hims &amp; Hers Health from $24.00 to $40.00 and gave the stock a &#34;market perform&#34; rating in a research note on Tuesday, February 25th. Bank of America boosted their price objective on Hims &amp; Hers Health from $22.00 to $26.00 and gave the stock an &#34;underperform&#34; rating in a research note on Tuesday, April 29th. TD Cowen cut Hims &amp; Hers Health from a &#34;buy&#34; rating to a &#34;hold&#34; rating and reduced their price objective for the stock from $44.00 to $30.00 in a research note on Tuesday, April 29th. Finally, Needham &amp; Company LLC reissued a &#34;buy&#34; rating and set a $61.00 price objective on shares of Hims &amp; Hers Health in a research note on Tuesday, May 6th. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of &#34;Hold&#34; and an average price target of $37.67.</p>
<div class="lb-trans"><p>多家研究机构最近对 HIMS 进行了评论。华尔街 Zen 在周四的研究报告中将 Hims &amp; Hers Health 的评级从 “持有” 上调至 “买入”。Leerink Partners 在 2 月 25 日的研究报告中将 Hims &amp; Hers Health 的目标价格从 24.00 美元上调至 40.00 美元，并给予该股票 “市场表现” 的评级。美国银行在 4 月 29 日的研究报告中将 Hims &amp; Hers Health 的目标价格从 22.00 美元上调至 26.00 美元，并给予该股票 “表现不佳” 的评级。TD Cowen 在 4 月 29 日的研究报告中将 Hims &amp; Hers Health 的评级从 “买入” 下调至 “持有”，并将该股票的目标价格从 44.00 美元下调至 30.00 美元。最后，Needham &amp; Company LLC 在 5 月 6 日的研究报告中重申了 “买入” 评级，并将 Hims &amp; Hers Health 的目标价格设定为 61.00 美元。两家股票研究分析师对该股票给予了卖出评级，八家给予了持有评级，四家给予了买入评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “持有”，平均目标价格为 37.67 美元。</p>
</div><p><strong>Get Our Latest Research Report on Hims &amp; Hers Health</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 Hims &amp; Hers Health 的最新研究报告</strong></p>
</div><h2>About Hims &amp; Hers Health</h2>
<div class="lb-trans"><h2>关于 Hims &amp; Hers Health</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Hims &amp; Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.</p>
<div class="lb-trans"><p>Hims &amp; Hers Health, Inc.运营一个远程医疗咨询平台。它将消费者与医疗专业人员连接，使他们能够获得心理健康、性健康、皮肤病学和初级护理的医疗服务。该公司成立于 2017 年，总部位于加利福尼亚州旧金山。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Hims &amp; Hers Health</li>
<li>Top Stocks Investing in 5G Technology</li>
<li>NVIDIA’s AI Robot Leap: 2 Stocks Set to Ride the Wave</li>
<li>Most Volatile Stocks, What Investors Need to Know</li>
<li>Turbulence for Joby Shares: What's Behind the Recent Dip?</li>
<li>3 Stocks to Consider Buying in October</li>
<li>Why Carnival Could Be the Ultimate Non-Tech Growth Stock</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Hims &amp; Hers Health</li>
<li>投资于 5G 技术的顶级股票</li>
<li>NVIDIA 的 AI 机器人跃进：两只股票将乘风而起</li>
<li>最具波动性的股票，投资者需要知道什么</li>
<li>Joby 股票的动荡：近期下跌背后的原因是什么？</li>
<li>十月值得考虑购买的三只股票</li>
<li>为什么嘉年华可能是终极非科技增长股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhJTVM" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=HIMS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Hims &amp; Hers Health Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 $1,000 在 Hims &amp; Hers Health 吗？</h2>
</div><p>Before you consider Hims &amp; Hers Health, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Hims &amp; Hers Health 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hims &amp; Hers Health wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Hims &amp; Hers Health 并不在名单上。</p>
</div><p>While Hims &amp; Hers Health currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Hims &amp; Hers Health 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Neo Ivy Capital Management 增加了其在 Hims & Hers Health, Inc.（NYSE:HIMS）的持股量